January 9, 2013
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Hologix (NASDAQ: HOLX ) -- a maker of diagnostics, medical imaging systems, and surgical products -- jumped as much as 11% following a favorable study supporting its 3-D mammography technology.
So what: A study based on 12,631 patients at an Oslo hospital revealed that researchers using Hologix 3-D mammography technology in combination with a 2-D mammogram had a "significant increase in cancer detection rates." According to the study's figures, it increased discovery of invasive cancers by 40%, increased total cancer discovery by 27%, and reduced false-positives by 15%.
Now what: Being the first large study on 3-D breast cancer screening, the results appear to indicate that patients would benefit from the use of Hologix's mammography technology in a broad application. Hologix investors definitely have carrot to nibble on now considering that growth is expected to slow into the single digits in 2014. At just 12 times forward earnings, it isn't particularly expensive, and, assuming further studies support today's findings, we could see a big revenue surge over the next three to five years because of its 3-D mammography technology.
What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.